FDA Approves Upadacitinib for Ulcerative Colitis
Upadacitinib has been shown to rapidly control symptoms in adults with moderate to severe active ulcerative colitis. It’s the first FDA approval for the JAK inhibitor in gastroenterology.
Stay updated with breaking news from Colitis Center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Upadacitinib has been shown to rapidly control symptoms in adults with moderate to severe active ulcerative colitis. It’s the first FDA approval for the JAK inhibitor in gastroenterology.
Patients aged 60 years and older with chronic or newly diagnosed IBD may have comorbidities or use medications that can interfere with IBD therapies.
In older patients with inflammatory bowel disease, adverse event rates were comparable between those treated with Stelara and those who received placebo, according to a recent analysis. “All of us who take care of patients with IBD are taking care of patients who are getting older and we are confronted with having to make choices of different medications, including biologic therapy, in
In African Americans, the genetic risk landscape for inflammatory bowel disease is very different from that of people with European ancestry, according to new findings. These results of the first whole-genome study of inflammatory bowel disease (IBD) in African Americans show that future clinical research on IBD needs to take ancestry into account, say the researchers. Findings of the multi-center study, which analyzed the whole genomes of more than 1,700 affected individuals with Crohn’s disease and ulcerative colitis and more than 1,600 controls, appear in the As part of their analysis, ...
E-Mail In African Americans, the genetic risk landscape for inflammatory bowel disease (IBD) is very different from that of people with European ancestry, according to results of the first whole-genome study of IBD in African Americans. The authors say that future clinical research on IBD needs to take ancestry into account. Findings of the multi-center study, which analyzed the whole genomes of more than 1,700 affected individuals with Crohn's disease and ulcerative colitis and more than 1,600 controls, were published on February 17 in the American Journal of Human Genetics. As part of t...